Semaglutide

Catalog No.S9697 Synonyms: Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217

For research use only.

Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).

Semaglutide Chemical Structure

CAS No. 910463-68-2

Purity & Quality Control

Choose Selective Glucagon Receptor Inhibitors

Biological Activity

Description Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217), a long-acting glucagon-like peptide 1 (GLP-1) analogue, is a GLP-1 receptor agonist with the potential for the treatment of type 2 diabetes mellitus (T2DM).
Targets
GLP-1 receptor [1]
In vitro

Semaglutide is selected as the optimal once weekly candidate. Semaglutide has two amino acid substitutions compared to human GLP-1 (Aib8, Arg34) and is derivatized at lysine 26. The GLP-1R affinity of semaglutide (0.38 ± 0.06 nM) is three-fold decreased compared to liraglutide, whereas the albumin affinity is increased.[2]

In vivo

The plasma half-life is 46.1 h in mini-pigs following i.v. administration, and semaglutide has an MRT of 63.6 h after s.c. dosing to mini-pigs.[2]

Protocol (from reference)

Cell Research:

[2]

  • Cell lines: BHK cells
  • Concentrations: 0.01 pM - 0.1 μM
  • Incubation Time: 3 h
  • Method:

    Frozen aliquots of BHK cells that express both the hGLP-1R and CRE firefly luciferase (clone FCW467-12A/KZ10-1) are thawed, washed twice in PBS, and suspended in assay buffer. Cells are plated out into 96-well plates at 5000 cells/well in a volume of 50 μL. Compounds to be tested are diluted in assay buffer and a 50 μL aliquot transferred to the plate containing the cells to reach final assay concentrations of 1 × 10−14 − 1 × 10−7 M. The plate is incubated for 3 h at 5% CO2 at 37 °C. The plate was allowed to stand at room temperature for 15 min prior to adding 100 μL of steadylite plus reagent. The plate is covered to protect it from light and shaken at room temperature for 30 min. The plate is read in a TopCount NXT instrument.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 4113.58
Formula

C187H291N45O59

CAS No. 910463-68-2
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04885634 Not yet recruiting Drug: Semaglutide Injectable Product|Drug: Placebo Atrial Fibrillation|Overweight and Obesity Axel Brandes|Herlev and Gentofte Hospital|Hillerod Hospital Denmark|Svendborg Hospital|Hospital of South West Jutland|Odense University Hospital October 2022 Phase 3
NCT05478252 Not yet recruiting Drug: Semaglutide J|Drug: Semaglutide B Diabetes Mellitus Type 2 Novo Nordisk A/S August 3 2022 Phase 3
NCT05254314 Not yet recruiting Drug: Semaglutide Pen Injector 2.4mg weekly|Other: Placebo Asthma Vanderbilt University Medical Center|National Institute of Allergy and Infectious Diseases (NIAID) August 2022 Phase 2
NCT05435677 Recruiting Drug: IcoSema|Drug: insulin icodec|Drug: semaglutide Diabetes Mellitus Type 2 Novo Nordisk A/S June 22 2022 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Semaglutide | Semaglutide supplier | purchase Semaglutide | Semaglutide cost | Semaglutide manufacturer | order Semaglutide | Semaglutide distributor